| Document |
Document Title |
|
JP2017025080A |
To provide pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) inhibitors effective in treatment of neurodegenerative diseases such as tauopathies including Alzheimer's disease.The invention provides pharmaceutical compo...
|
|
JP2016529234A |
The present invention relates to novel compounds of formula I and their N-oxides, stereoisomers, tautomers and agronomically or veterinarily acceptable salts, in formula C.1Is C or CH; C2Is C or CH; A1Is N or C; A2Is N, C (R2), N (R)3), ...
|
|
JP2016527208A |
The present invention relates to the iso thiazoline compound of formula I which is as the variable machine being defined in the claim and the statement. This compound is useful although a non-backbone noxious organism especially a Arthro...
|
|
JP2016155832A |
To provide an estrogen receptor modulator compound that is involved in a number of diseases and disorders, such as breast cancer, ovarian cancer, colon cancer, prostate cancer, endometrial cancer, uterine cancer, as well as other disease...
|
|
JP2016522814A |
The present invention relates to known N- (2-substituted 2-phenylethyl) carboxamides and N- (2-substituted 2-phenylethyl) thiocarboxamides for controlling nematodes that damage plants in agriculture. Regarding the use of novel N- (2-subs...
|
|
JP2016522180A |
Sodium sulfide hydrate is at least partially dehydrated by heating with N-methyl-2-pyrrolidone. 2-Chlorobenzamide is added to the mixture and further heated. The mixture is cooled and treated with aqueous hydrogen peroxide solution to pr...
|
|
JP5955972B2 |
Sodium sulfide hydrate is at least partially dehydrated by heating with N-methyl 2-pyrrolidone. 2-chlorobenzamide is added to the mixture which is heated further. The mixture is cooled and treated with aqueous hydrogen peroxide to give t...
|
|
JP5947346B2 |
This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for pre...
|
|
JP5940452B2 |
This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the disclosure of each of which is incorporated by ...
|
|
JP2016518385A |
As the extermination-of-harmful-insects medicine to an animal and the internal parasitism living thing in humans in order that the present invention may control the nematodes in agriculture, Use of N* (phenyl cycloalkyl) Carboxamide and ...
|
|
JP2016517420A |
The compound which is an estrogen receptor modulator is described by this specification. In order to treat the disease or state which is carried by the estrogen receptor or for which it depends, How to use the pharmacological constituent...
|
|
JP2016517412A |
The present invention relates to the compound for FASN prevention, constituents, those composition, application, and an antidote. An example of the compound of the present invention is shown below. [Drawing 1]
|
|
JP2016094407A |
To provide a novel α-substituted glycine amide derivative, or a pharmaceutical composition containing pharmacologically acceptable salt thereof, and a medicinal use thereof.The present invention provides a compound expressed by a genera...
|
|
JP5905437B2 |
[Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secret...
|
|
JP5890312B2 |
The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have act...
|
|
JP2016506921A |
The present invention has a general formula (I) that inhibits mitotic checkpoints. [Chemical 1]Isothiazole, wherein A, R1 and R2 are as defined in the claims, isothiazole, a method for preparing the compound, an intermediate compound use...
|
|
JP2016028072A |
To provide a novel compound having a GPR40 activating action, particularly an insulin secretion promoter and an agent useful for prevention and/or therapy of diabetes, obesity, or the like.The present invention provides a compound of for...
|
|
JP5845283B2 |
wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, ...
|
|
JP5816557B2 |
The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of s...
|
|
JP5807971B2 |
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these c...
|
|
JP5800895B2 |
The use of a complex of the form Z—M—OR in the carboxylation of a substrate is described. The group Z is a two-electron donor ligand, M is a metal and OR is selected from the group consisting of OH, alkoxy and aryloxy. The substrate ...
|
|
JP5782430B2 |
Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases...
|
|
JP5778103B2 |
3,4-Dichloro-N-(2-cyanophenyl)-5-isothiazole-carboxamide (I) is prepared by (a) reacting 3,4-isothiazole-5-carbonyl chloride (II) with anthanilamide (III) and (b) dehydrating the obtained amide (IV), where (i) at least step (a) is carrie...
|
|
JP5759893B2 |
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Hu...
|
|
JP5753632B2 |
[Problem to be Solved] To provide an industrially preferred process for producing an isothiazole compound, particularly 3,4-dichloro-5-cyanoisothiazole. For example, to provide a safer industrial production process by avoiding the simult...
|
|
JP5717031B2 |
Provided are a substituted azole derivative and pharmaceutically acceptable salts thereof, a pharmaceutical composition including an effective amount of the derivative, and a method for treating Parkinson's disease in a mammal including ...
|
|
JP5709846B2 |
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also rela...
|
|
JP2015044829A |
To provide a compound having biaryl phosphodiesterase-4 (PDE4) inhibitory action useful for treatment and prevention of stroke, myocardial infraction and cardiovascular inflammatory diseases.There is provided a biaryl compound having at ...
|
|
JP5682665B2 |
To provide a sulfonic compound useful as an intermediate raw material for a medicine, an agrochemical, an electronic material, a polymer material or the like, or as a battery material, and further to provide a nonaqueous electrolyte exce...
|
|
JP5681242B2 |
The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are att...
|
|
JP5675181B2 |
|
|
JP2015036377A |
To provide a pest control agent for controlling harmful organisms in agricultural and horticultural fields or harmful organisms to an animal such as a pet and a domestic animal or a domestic animal.There is provided a substituted phenyl-...
|
|
JP5667044B2 |
The present invention relates to substituted phenoxybenzamide compounds of general formula (I): in which R1, R2, R3, R4, R5, X, R6 and q are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions...
|
|
JP5664312B2 |
|
|
JP2015501316A |
The present invention provides compounds useful for the treatment of hepatitis C virus (HCV) infections. This compound has the formula (1) [formulation] or a salt thereof, an N-oxide, a metamutant or a steric isomer, in which A is CH or ...
|
|
JP5638250B2 |
|
|
JP5613177B2 |
Disclosed are compounds of Formula (1), in which A 1 , Z 1 , Z 1A , Z 2 , Z 2A , L 1 and Z 3 are as defined in the claims, which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and their use i...
|
|
JP5605029B2 |
The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group which may have one or more halogen atoms, A1 represents a divalent connecting group, X...
|
|
JP2014525932A |
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one ...
|
|
JP5592253B2 |
This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorder...
|
|
JP5583118B2 |
A process for producing 3,4-dichloro-5-cyanoisothiazole represented by a general formula (3): the process comprising: reacting a nitrile compound represented by a general formula (1): (wherein "n" denotes an integer of 0 to 2), with sulf...
|
|
JP5580834B2 |
The present invention relates to a compound represented by formula (I): (wherein R, R2, R3 and R4 each independently represent a hydrogen or halogen atom; R5 and R6 each independently represent a hydrogen atom or lower alkyl or together ...
|
|
JP5566288B2 |
The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.
|
|
JP5563282B2 |
|
|
JPWO2012147516A1 |
To provide a GPR40 activator containing a novel compound having a GPR40 agonistic action or a salt thereof or a solvate thereof as an active ingredient, particularly an insulin secretagogue, a preventive and / or therapeutic agent for di...
|
|
JPWO2012127969A1 |
The present invention is a method for producing a 1,2-benzisothiazole-3-one compound by reacting a 2- (alkylthio) benzonitrile compound with a halogenating agent in the presence of water. The present invention provides a method comprisin...
|
|
JPWO2012127996A1 |
The present invention is obtained as a by-product when a 2- (alkylthio) benzonitrile compound and a halogenating agent are reacted in the presence of water to produce a 1,2-benzisothiazole-3-one compound. Alkyl halide is reacted with a s...
|
|
JP5559998B2 |
|
|
JP5559346B2 |
The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
|
|
JP5550880B2 |
The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy...
|
